Novo Nordisk Partners with Omega Therapeutics and Cellarity for Innovative Treatment Approaches in Obesity and MASH
Novo Nordisk, a global leader in healthcare, has announced new research collaborations with Omega Therapeutics and Cellarity to develop innovative treatment approaches for obesity and metabolic dysfunction-associated steatohepatitis (MASH). These collaborations are the first two programmes signed under the existing partnership between Novo Nordisk and Flagship Pioneering, a leading life sciences venture capital firm.
The collaboration with Omega Therapeutics will focus on developing an epigenomic controller designed to enhance metabolic activity as a potential new treatment for obesity management. This approach harnesses the body’s natural mechanisms to control gene expression and has the potential to provide a more durable solution for weight management. This partnership highlights Novo Nordisk’s commitment to advancing new treatment options for people living with cardiometabolic diseases.
In addition, the collaboration with Cellarity aims to unravel novel biological drivers of MASH and develop a small molecule therapy against this chronic and progressive liver disease. Cellarity’s unique platform, which combines biology, chemistry, and high-dimensional data, allows for the identification of new targets and mechanisms that may not be apparent through traditional approaches. This partnership further demonstrates Novo Nordisk’s dedication to developing innovative treatment options for patients with cardiometabolic diseases.
Novo Nordisk will reimburse R&D costs for these collaborations and both Omega Therapeutics and Cellarity are eligible to receive up to 532 million US dollars in upfront and milestone payments, as well as tiered royalties. “We are excited to collaborate with Omega Therapeutics and Cellarity to explore bold new treatment strategies for obesity and MASH,” said Marcus Schindler, executive vice president and chief scientific officer at Novo Nordisk. “By leveraging their cutting-edge technologies and expertise, we hope to make a significant impact for patients living with these conditions.”
These collaborations are a part of Novo Nordisk’s ongoing efforts to complement its internal research with external innovation and work with partners who are bringing forward novel approaches to healthcare. The company remains committed to advancing new treatment options for people living with cardiometabolic diseases.
Novo Nordisk’s new collaborations with Omega Therapeutics and Cellarity demonstrate the company’s dedication to developing innovative treatment approaches for obesity and MASH. By leveraging cutting-edge technologies and expertise, Novo Nordisk aims to make a significant impact for patients living with these conditions.
